OPK Nasdaq Pharmaceutical Preparations Financials FY2016βFY2025
Opko Health, Inc. had $607M of revenue in fiscal 2025, down 14.9% on the year before. Over five years, revenue changed β15.8% a year on average.
Last close Β· Oct 23, 2026
$1.63
0.0%Hi! I read Opko Health, Inc.βs latest annual report (fiscal 2025). Here is what stands out:
Good So-so Weak
Are sales growing?
β14.9%
No. Sales fell 14.9% last year.
Does it make a profit?
β37.2%
No. It lost money last year.
Does profit turn into cash?
β31.4%
No. It spent more cash than it brought in.
How healthy are the accounts?
4 / 9
Mixed. It passes 4 of 9 health tests.
How is the share priced?
β
No P/E: it made no profit over the last four quarters.
Rules of thumb on reported numbers. A starting point, not a recommendation.
Is it selling more, and how much does it keep?
KIRA Β· Opko Health, Inc. had $607M of revenue in fiscal 2025, down 14.9% on the year before. Over five years, revenue changed β15.8% a year on average. Its operating margin was β19.3%, up 2.0Β pts: of every 100 in sales, about β19 is left after running the business.
In plain words: Revenue is all the money customers paid. The margins show how many cents of each dollar of sales are left over at each step: after making the product (gross), after running the business (operating) and after everything, tax included (net).
Revenue
Revenue
Margins, % of revenue
Margins, % of revenue
KIRA Β· Opko Health, Inc. lost $226M in fiscal 2025.
Loss periods are shown in red.
In plain words: Net income is the profit left after every cost and tax. Earnings per share (EPS) splits that profit across every share, so it shows what one share earned.
Net income
Net income
Diluted EPS
Diluted EPS
How much cash comes in, and where does it go?
KIRA Β· Free cash flow was β$191M in fiscal 2025, β31.4% of revenue.
Cash from operations minus capital spending.
In plain words: Profit on paper is not the same as cash in the bank. Free cash flow is the cash left after paying to run and maintain the business: the money it can hand back to shareholders, save or invest.
Free cash flow
Free cash flow
Cash from operations vs capital spending
Cash from operations vs capital spending
KIRA Β· Opko Health, Inc. returned $47.0M to shareholders in fiscal 2025. The diluted share count rose 8.2%.
In plain words: Companies hand cash back in two ways: dividends (cash paid to shareholders) and buybacks (buying back their own shares, so each remaining share owns a bigger slice).
Dividends and buybacks
Dividends and buybacks
Diluted shares outstanding (annual)
KIRA Β· In the last 12 months, insiders bought $3.2M of shares on the open market and sold none.
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. βPlanβ marks trades under a pre-arranged Rule 10b5-1 plan.
In plain words: Insiders are the people who run or own a big part of the company. Buying with their own money can signal confidence; selling often has personal reasons, like taxes or diversifying.
Bought, 12 months
$3.2M
3 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
β
$0.0M
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Mar 20, 2026 | John A PaganelliDirector | Bought | 10,000 | $1.14 | $0.0M | Form 4 |
| Nov 21, 2025 | Frost Gamma Investments Trust10% owner | Bought | 580,000 | $1.33 | $0.8M | Form 4 |
| Nov 20, 2025 | Frost Gamma Investments Trust10% owner | Bought | 580,000 | $1.33 | $0.8M | Form 4 |
| Nov 19, 2025 | Frost Gamma Investments Trust10% owner | Bought | 580,000 | $1.31 | $0.8M | Form 4 |
| Nov 18, 2025 | Frost Gamma Investments Trust10% owner | Bought | 533,300 | $1.28 | $0.7M | Form 4 |
| Oct 31, 2025 | Phillip MD Et Al FrostCEO & Chairman, Director, 10% owner | Bought | 150,000 | $1.42 | $0.2M | Form 4 |
Can it carry its debts, and how well does it use its money?
KIRA Β· Opko Health, Inc. has $15.4M more cash than debt.
Cash, debt and the ratios that show how comfortably Opko Health, Inc. can carry it.
In plain words: What the company owns and what it owes. More cash than debt is a cushion for bad times; a lot of debt leaves less room when business slows down.
Cash vs debt (incl. leases)
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | $135M | $153M | $95.9M | $427M | $364M |
| Debt incl. finance leases | $210M | $266M | $10.2M | $443M | $349M |
| Net debt / EBITDA | 0.8x | β | β | β | β |
| Debt / equity | 0.1x | 0.2x | 0.0x | 0.3x | 0.3x |
| Interest coverage | 1.0x | β18.8x | β11.6x | β3.2x | β |
| Current ratio | 2.5x | 1.8x | 1.5x | 3.4x | 4.0x |
| Quick ratio | 2.2x | 1.5x | 1.2x | 3.1x | 3.5x |
| Total assets | $2.4B | $2.2B | $2.0B | $2.2B | $1.9B |
| Total liabilities | $715M | $606M | $622M | $835M | $664M |
| Shareholders' equity | $1.7B | $1.6B | $1.4B | $1.4B | $1.3B |
| Net debt (β = net cash) | $75.7M | $113M | β$85.7M | $16.4M | β$15.4M |
KIRA Β· Its return on capital was β7.4%: every 100 invested in the business earned about β7 in a year.
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
In plain words: How much profit the business makes on the money put into it. A higher percentage means each dollar invested works harder.
Return on capital, equity and assets (annual)
KIRA Β· Opko Health, Inc. passes 4 of 9 financial health tests (Piotroski F-score).
Nine pass/fail tests of profitability, funding and efficiency. 8β9 is strong, 0β2 weak.
In plain words: Nine yes/no tests of financial health, one point each. A green tick is a pass: 7 to 9 points is solid, 0 to 3 is weak.
| Test | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net income is positive | β | β | β | β | β | β | β | β | β | β |
| Cash from operations is positive | β | β | β | β | β | β | β | β | β | β |
| Return on assets rose | β | β | β | β | β | β | β | β | β | β |
| Cash from operations exceeds net income | β | β | β | β | β | β | β | β | β | β |
| Debt fell relative to assets | β | β | β | β | β | β | β | β | β | β |
| Current ratio rose | β | β | β | β | β | β | β | β | β | β |
| Share count didn't rise | β | β | β | β | β | β | β | β | β | β |
| Gross margin rose | β | β | β | β | β | β | β | β | β | β |
| Revenue rose relative to assets | β | β | β | β | β | β | β | β | β | β |
| F-score | β / 3 | 2 / 9 | 4 / 8 | 2 / 8 | 7 / 8 | 5 / 8 | 1 / 8 | 4 / 9 | 3 / 9 | 4 / 9 |
| Accruals ratio | β2.9% | β8.0% | β1.7% | β6.0% | β0.4% | β2.8% | β10.2% | β7.7% | 6.2% | β2.3% |
| Altman Z'' | 2.61 | 0.65 | 0.87 | β0.28 | 0.79 | 1.82 | β0.19 | β1.08 | β0.41 | β0.79 |
Every number, year by year.
Amounts in USD. Hover a ratioβs name for its definition.
In plain words: Every number we have, year by year. Download it as a spreadsheet if you want to dig deeper.
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | $1.1B | $966M | $990M | $902M | $1.4B | $1.8B | $1.0B | $863M | $713M | $607M |
| Gross profit | $553M | $905M | β | β | β | β | $288M | $318M | $219M | $206M |
| Research and development | $114M | $126M | $126M | $118M | $75.3M | $76.9M | $73.9M | $89.6M | $105M | $124M |
| Operating income | β$96.6M | β$276M | β$171M | β$274M | $57.7M | $18.8M | β$226M | β$157M | β$152M | β$117M |
| Interest expense | β | β | β | β | β | $18.9M | $12.1M | $13.5M | $47.5M | $0.0M |
| Pretax income | β$96.8M | β$272M | β$177M | β$305M | $48.7M | β$14.0M | β$392M | β$184M | β$10.4M | β$241M |
| Income tax | β$56.1M | $18.9M | β$38.7M | $7.1M | $17.6M | $15.5M | β$63.5M | $4.4M | $42.8M | β$15.7M |
| Net income | β$48.4M | β$305M | β$153M | β$315M | $30.6M | β$30.1M | β$328M | β$189M | β$53.2M | β$226M |
| Net income to common | β$25.1M | β$309M | β | β | β | β | β | β | β | β |
| Diluted EPS | β$0.10 | β$0.55 | β$0.27 | β$0.53 | $0.05 | β$0.05 | β$0.46 | β$0.25 | β$0.08 | β$0.30 |
| Diluted shares | 0.56B | 0.56B | 0.56B | 0.60B | 0.64B | 0.65B | 0.72B | 0.75B | 0.69B | 0.75B |
| Cash flow | ||||||||||
| Cash from operations | $32.0M | β$92.1M | β$109M | β$173M | $39.5M | $38.3M | β$95.2M | β$28.2M | β$183M | β$179M |
| Capital expenditure | $18.5M | $46.5M | $27.9M | $12.7M | $33.7M | $32.2M | $24.6M | $16.3M | $25.0M | $12.3M |
| Free cash flow | $13.5M | β$139M | β$137M | β$185M | $5.8M | $6.2M | β$120M | β$44.5M | β$208M | β$191M |
| Depreciation and amortization | $96.6M | $102M | $97.3M | $93.8M | $85.4M | $78.7M | $109M | $105M | $98.2M | $91.6M |
| Stock-based compensation | $42.7M | $28.3M | $21.8M | $13.4M | $8.9M | $13.6M | $18.5M | $11.4M | $11.0M | $10.7M |
| Acquisitions | β$15.9M | $0.0M | $0.0M | $0.0M | $0.0M | $4.0M | $1.8M | $0.0M | $0.0M | β |
| Share buybacks | β | β | β | β | β | β | $0.0M | $0.0M | $90.2M | $47.0M |
| Dividends and buybacks | β | β | β | β | β | β | $0.0M | $0.0M | $90.2M | $47.0M |
| Balance sheet | ||||||||||
| Cash and short-term investments | $169M | $91.5M | $96.5M | $85.5M | $72.2M | $135M | $153M | $95.9M | $427M | $364M |
| Total debt | $12.7M | $13.5M | $10.5M | $270M | $251M | $205M | $256M | $0.1M | $437M | $344M |
| Finance lease liabilities | β | β | β | $6.8M | $5.3M | $5.2M | $9.9M | $10.1M | $5.7M | $5.1M |
| Current assets | $484M | $349M | $318M | $324M | $523M | $823M | $395M | $309M | $662M | $582M |
| Current liabilities | $263M | $312M | $288M | $249M | $375M | $330M | $213M | $200M | $193M | $147M |
| Inventory | $47.2M | $49.3M | $42.3M | $53.4M | $132M | $86.5M | $74.1M | $65.7M | $56.8M | $65.8M |
| Property and equipment, net | $123M | $147M | $145M | $127M | $141M | β | $82.9M | $75.4M | $70.1M | $73.9M |
| Goodwill | $705M | $717M | $700M | $672M | $681M | $521M | $596M | $598M | $529M | $484M |
| Intangible assets | $764M | $684M | $614M | $529M | $475M | $322M | $824M | $740M | $617M | $516M |
| Total assets | $2.8B | $2.6B | $2.5B | $2.3B | $2.5B | $2.4B | $2.2B | $2.0B | $2.2B | $1.9B |
| Total liabilities | $675M | $746M | $660M | $695M | $802M | $715M | $606M | $622M | $835M | $664M |
| Shareholders' equity | $2.0B | $1.8B | $1.8B | $1.6B | $1.7B | $1.7B | $1.6B | $1.4B | $1.4B | $1.3B |
| Margins | ||||||||||
| Gross margin | 49.5% | 93.7% | β | β | β | β | 28.7% | 36.8% | 30.6% | 33.9% |
| Operating margin | β8.6% | β28.6% | β17.3% | β30.4% | 4.0% | 1.1% | β22.5% | β18.2% | β21.3% | β19.3% |
| EBITDA margin | 0.0% | β18.0% | β7.5% | β20.0% | 10.0% | 5.5% | β11.7% | β6.0% | β7.6% | β4.2% |
| Net margin | β4.3% | β31.6% | β15.5% | β34.9% | 2.1% | β1.7% | β32.7% | β21.9% | β7.5% | β37.2% |
| FCF margin | 1.2% | β14.3% | β13.8% | β20.5% | 0.4% | 0.3% | β11.9% | β5.2% | β29.2% | β31.4% |
| Returns | ||||||||||
| Return on capital | β4.0% | β12.4% | β7.9% | β12.0% | 2.0% | 0.8% | β10.7% | β9.6% | β8.7% | β7.4% |
| Return on capital employed | β3.9% | β12.1% | β7.9% | β13.3% | 2.8% | 0.9% | β11.6% | β8.7% | β7.6% | β6.6% |
| Return on equity | β2.4% | β15.7% | β8.4% | β18.5% | 1.9% | β1.8% | β20.2% | β12.8% | β3.9% | β17.1% |
| Return on assets | β1.7% | β11.4% | β6.1% | β13.2% | 1.3% | β1.2% | β14.4% | β9.0% | β2.5% | β10.9% |
| Return on tangible equity | β4.3% | β69.8% | β32.1% | β76.1% | 5.9% | β3.6% | β230.8% | β372.7% | β24.2% | β84.4% |
| Growth | ||||||||||
| Revenue growth | β | β13.6% | 2.5% | β8.9% | 59.1% | 23.6% | β43.4% | β14.0% | β17.4% | β14.9% |
| Net income growth | β | β | β | β | β | β198.6% | β | β | β | β |
| EPS growth | β | β | β | β | β | β200.0% | β | β | β | β |
| FCF growth | β | β1,126.8% | β | β | β | 6.7% | β2,037.7% | β | β | β |
| Share count change | β | 0.6% | 0.7% | 5.7% | 7.6% | 1.2% | 11.0% | 4.5% | β7.7% | 8.2% |
| Financial health | ||||||||||
| Net debt / EBITDA | β6,241.4x | β | β | β | 1.3x | 0.8x | β | β | β | β |
| Debt / equity | 0.0x | 0.0x | 0.0x | 0.2x | 0.2x | 0.1x | 0.2x | 0.0x | 0.3x | 0.3x |
| Interest coverage | β | β | β | β | β | 1.0x | β18.8x | β11.6x | β3.2x | β |
| Current ratio | 1.8x | 1.1x | 1.1x | 1.3x | 1.4x | 2.5x | 1.8x | 1.5x | 3.4x | 4.0x |
| Quick ratio | 1.7x | 1.0x | 1.0x | 1.1x | 1.0x | 2.2x | 1.5x | 1.2x | 3.1x | 3.5x |
| Capital allocation | ||||||||||
| Capex / revenue | 1.7% | 4.8% | 2.8% | 1.4% | 2.3% | 1.8% | 2.4% | 1.9% | 3.5% | 2.0% |
| Stock comp / revenue | 3.8% | 2.9% | 2.2% | 1.5% | 0.6% | 0.8% | 1.8% | 1.3% | 1.5% | 1.8% |
| Quality scores | ||||||||||
| Piotroski F-score | β | 2.0 | 4.0 | 2.0 | 7.0 | 5.0 | 1.0 | 4.0 | 3.0 | 4.0 |
| Altman Z'' | 2.6 | 0.6 | 0.9 | β0.3 | 0.8 | 1.8 | β0.2 | β1.1 | β0.4 | β0.8 |
| Accruals ratio | β2.9% | β8.0% | β1.7% | β6.0% | β0.4% | β2.8% | β10.2% | β7.7% | 6.2% | β2.3% |
Source: SEC EDGAR XBRL filings (CIK 0000944809). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only β not investment advice. Check the original filings before relying on any figure.
